Genezen

Genezen, established in Indianapolis in 2014, is a gene and cell therapy contract development and manufacturing organization (CDMO) specializing in the production of lentiviral and retroviral vectors. It focuses on supporting the needs of the global current and future gene and cell therapy manufacturing market, providing viral vector production access to early-stage growing companies as well as established industry leaders. Based on the company's extensive knowledge and experience in the industry and collaboration with leading institutions in the United States, Genezen offers early-stage process development, GMP vector manufacturing, and analytical testing services from its state-of-the-art laboratory facility completed at the end of 2022.